NDC 17856-0353-2 - Pharbetol Regular strength
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 17856-0353
- Requested NDC
- 17856-0353-2
- Package NDCs from labels
- 17856-0353-2, 17856-0353-1, 17856-0353-4, 17856-0353-3
- Manufacturer
- ATLANTIC BIOLOGICALS CORP.
- Effective date
- 2025-06-05
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| PHARBEST IBUPROFEN Drug Facts | ATLANTIC BIOLOGICALS CORP. | 2025-06-05 | HUMAN OTC DRUG LABEL |
| Pharbetol Regular strength - ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | ATLANTIC BIOLOGICALS CORP. | UNIT DOSE SOLUTIONS | 2024-04-30 | HUMAN OTC DRUG LABEL |
FDA-Initiated Inactive NDC Indexing#
| NDC | Effective | Action | Document | Indexing SPL | Related label |
|---|---|---|---|---|---|
| 17856-0353-1 | 2024-06-26 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
| 17856-0353-1 | 2024-01-30 | C162847 | 48780-1 | 1030e365-250f-111a-e063-dadaa90a10e2 | PHARBEST IBUPROFEN Drug Facts |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 17856-0353-1 | PharbetolRegular strength | 100 in 1 BOX, UNIT-DOSE | TABLET | 100 | 3 | |
| 17856-0353-2 | PharbetolRegular strength | 1 in 1 POUCH | TABLET | 1 | 3 | |
| 17856-0353-4 | PharbetolRegular strength | 24 in 1 BOTTLE | TABLET | 24 | 3 | |
| 17856-0353-3 | PharbetolRegular strength | 28 in 1 BOTTLE | TABLET | 28 | 1 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 2 | Current NDC, Legacy NDC, 3 package rows | 20240627_05a91d24-b498-4ba2-a275-68b871cf62d2.zip |
| 17856-0353 | PHARBETOL REGULAR STRENGTH (ACETAMINOPHEN) TABLET [ATLANTIC BIOLOGICALS CORP.] | 1 | Current NDC, Legacy NDC, 1 package rows | 20240508_bd26081c-e81e-42e8-b3da-2813863a51df.zip |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| sinus pressure and pain pe | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | GOODSENSE | a7931e4c-8a5e-66e2-e053-2995a90af2a4 | 2024-10-18 | Warnings | 362O9ITL9D |
| Sinus Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | GoodSense | 570ea130-6a99-446e-9f97-14fc95809006 | 2024-10-18 | Warnings | 362O9ITL9D |
| Sinus and Headache | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | GOODSENSE | a14999e3-a9d9-0a1f-e053-2995a90af7b3 | 2024-10-18 | Warnings | 362O9ITL9D |
| Allergy Multi Symptom | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE HYDROCHLORIDE | GOODSENSE | a793000b-3ef9-5662-e053-2a95a90ad0da | 2024-10-18 | Warnings | 362O9ITL9D |
| Pain Relief Extra Strength | ACETAMINOPHEN | GoodSense | da4339c0-1822-41d8-8c20-214c379a5aa7 | 2024-10-18 | Warnings | M013 362O9ITL9D |
| Head Congestion Mucus PE | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | GOODSENSE | e3396a27-8643-71fa-e053-2a95a90a713d | 2024-10-18 | Warnings | 362O9ITL9D |
| Pain Relief PM Extra Strength | ACETAMINOPHEN AND DIPHENHYDRAMINE HYDROCHLORIDE | GoodSense | 8972d95a-51da-40b5-8ef1-9dfed220d7eb | 2024-10-18 | Warnings | M013 362O9ITL9D |
| Head Congestion Flu Severe PE | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | GOODSENSE | e3397f69-3267-ca0b-e053-2995a90a7db5 | 2024-10-18 | Warnings | 362O9ITL9D |
| Cold and Head Congestion Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | GoodSense | 747512a2-3b6d-496b-ab80-819060314163 | 2024-10-18 | Warnings | 362O9ITL9D |
| Pain Relief Regular Strength | ACETAMINOPHEN | AmeriSource Bergen | d571f520-a56e-4f7f-9214-d89197f742b6 | 2024-10-18 | Warnings | M013 313782 362O9ITL9D |
| Allergy Multi Symptom | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, AND PHENYLEPHRINE HYDROCHLORIDE | AMERISOURCE BERGEN | 9daf7f40-d9c5-4367-be41-894208358fc1 | 2024-10-18 | Warnings | 362O9ITL9D |
| Cold Flu Severe | ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | AmeriSource Bergen | 665db127-ee04-46c4-bff0-e0fe9950c3e2 | 2024-10-18 | Warnings | 362O9ITL9D |
| Cold Head Congestion Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | AmeriSource Bergen | 604d7e53-4bfd-4cdd-aed2-b304ae82ce44 | 2024-10-18 | Warnings | 362O9ITL9D |
| LOW DOSE ASPIRIN | ASPIRIN | Bryant Ranch Prepack | 6b4b7f72-dac8-4b59-a58c-7c59d4b1ef32 | 2024-10-18 | Warnings | M013 |
| BUTALBITAL AND ACETAMINOPHEN | BUTALBITAL AND ACETAMINOPHEN | Burel Pharmaceuticals, LLC | 0a8a6a16-b23f-45d2-b5d4-540264e74d14 | 2024-10-18 | Boxed warning, Warnings, Adverse reactions | 362O9ITL9D |
| dg health pain relief | ACETAMINOPHEN | Dolgencorp Inc | 2e1470f5-e88f-4d1d-a308-170f7080387e | 2024-10-17 | Warnings | M013 362O9ITL9D |
| Chewable Aspirin | ASPIRIN | DISCOUNT DRUG MART | c8483d64-874c-3056-e053-2995a90ad8aa | 2024-10-17 | Warnings | M013 |
| Sinus Severe | ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE | DISCOUNT DRUG MART | 62c35320-87b5-46e2-9f6f-cb0882bdb52e | 2024-10-17 | Warnings | 362O9ITL9D |
| Cold Max Nighttime | ACETAMINOPHEN, CHLORPHENIRAMINE MALEATE, DEXTROMETHORPHAN HYDROBROMIDE, AND PHENYLEPHRINE HYDROCHLORIDE | DISCOUNT DRUG MART | e3dcf6cf-373c-ea83-e053-2a95a90ae57a | 2024-10-17 | Warnings | 362O9ITL9D |
| Sinus Pressure plus Pain PE | ACETAMINOPHEN AND PHENYLEPHRINE HYDROCHLORIDE | DISCOUNT DRUG MART | a7e99dad-5918-6a90-e053-2a95a90a8803 | 2024-10-17 | Warnings | 362O9ITL9D |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.